Lupus Clinical Investigators Network Archives

Tag: Lupus Clinical Investigators Network

Lupus Therapeutics Statement on Positive Data from Phase 3 PHOENYCS GO Trial in Moderate-To-Severe Systemic Lupus

WASHINGTON, D.C., November 19, 2024 — Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3 PHOENYCS GO results reported by UCB and Biogen during ACR Convergence 2024. Study sponsors presented results of the pivotal trial designed to evaluate the efficacy and safety of dapirolizumab pegol […] Read More

On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

May 1, 2024 — As part of Lupus Awareness Month, May 1 has been declared “Lupus Call to Action Day” by the National Minority Health Association (NMHA) and members of the lupus community. Kicking off at NYU Langone Health in New York City, the high-profile platform is designed to drive awareness and enact change to […] Read More

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, NY, June 2, 2023 — Lupus Research Alliance clinical research affiliate Lupus Therapeutics will collaborate with Novartis Pharmaceuticals Corporation to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America. Read More

Data at ACR 2022 Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and clinical researchaffiliate Lupus Therapeutics will present data at ACR Convergence 2022 showing that the pilot peer education program Patient Advocates for Lupus Studies (PALS), increased knowledge, perception, and intentions among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials. These study results […] Read More

NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

August 31, 2022 We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

LRA is Unraveling Lupus Heterogeneity to Turn Complexity to Cure

July 22, 2021 Why is lupus so tough to treat? Why is it so difficult to test possible new treatments in a clinical trial? Why are so many people needed for a clinical trial to prove effectiveness? And how does LRA intend to Turn Lupus Complexity to Cure? The answers lie at the core of […] Read More

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials

June 22, 2020 African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical trials of the disease. However, a new study showed that several simple steps, such as providing transportation and flexible scheduling, may allow more African-Americans to participate in trials. The study was conducted by top lupus […] Read More

Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis

NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […] Read More

PALS Clinical Trial Program Opens at Five Universities

August 8, 2019 In five pilot cities, people with lupus who are thinking about taking part in a clinical trial can now join LRA’s Patient Advocates for Lupus Studies (PALS) program created by our affiliate Lupus Therapeutics. The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who […] Read More